Nivalis Therapeutics Inc (NVLS)

2.40
0.08 3.40
NASDAQ : Health Care
Prev Close 2.32
Open 2.33
Day Low/High 2.33 / 2.47
52 Wk Low/High 3.68 / 20.43
Volume 90.76K
Avg Volume 305.70K
Exchange NASDAQ
Shares Outstanding 15.66M
Market Cap 36.17M
EPS -2.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Nivalis Therapeutics, Inc. And Alpine Immune Sciences, Inc. Agree To Combine

Nivalis Therapeutics, Inc. And Alpine Immune Sciences, Inc. Agree To Combine

Nivalis Therapeutics, Inc. (NASDAQ: NVLS) and Alpine Immune Sciences, Inc.

Nivalis Therapeutics Reports Fourth Quarter And Full-Year 2016 Financial Results

Nivalis Therapeutics Reports Fourth Quarter And Full-Year 2016 Financial Results

Review of Strategic Alternatives Progressing as Operations Streamlined

These 5 Stocks Under $10 Could Make You a Lot of Money

These 5 Stocks Under $10 Could Make You a Lot of Money

Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.

Nivalis Therapeutics Announces Results From Phase 2 Clinical Trial Of Cavosonstat For Treatment Of Cystic Fibrosis

Nivalis Therapeutics Announces Results From Phase 2 Clinical Trial Of Cavosonstat For Treatment Of Cystic Fibrosis

Company to Host Conference Call Today, November 28, at 5:00 p.m. EST

Nivalis Therapeutics Reports Third Quarter 2016 Financial Results

Nivalis Therapeutics Reports Third Quarter 2016 Financial Results

Completion of Enrollment in Phase 2 Study of Cavosonstat for Treatment of Cystic Fibrosis Achieved During the Quarter

7 Stocks Under $10 Making Big Up Moves

7 Stocks Under $10 Making Big Up Moves

Here's a technical look at how to trade several under-$10 stocks that were making big moves to the upside recently.

7 Stocks Under $10 to Trade for Big Post-Brexit Gains

7 Stocks Under $10 to Trade for Big Post-Brexit Gains

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Nivalis Therapeutics Reaches 50 Percent Enrollment Milestone In Phase 2 Clinical Trial In Cystic Fibrosis

Nivalis Therapeutics Reaches 50 Percent Enrollment Milestone In Phase 2 Clinical Trial In Cystic Fibrosis

Company on track to report results from the study in fourth quarter this year

Need For Patient-Centric Clinical Trials Fuels Adoption Of Greenphire's ClinCard Solution

Need For Patient-Centric Clinical Trials Fuels Adoption Of Greenphire's ClinCard Solution

Industry-leading patient reimbursement solution reaches milestone of 3 million transactions, totaling more than $200 million in patient reimbursements worldwide